Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Hits Estimates

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings data on Monday. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55, Briefing.com reports. The business had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.74 EPS.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $24.91 on Thursday. The firm’s fifty day moving average price is $32.67 and its two-hundred day moving average price is $38.15. Integra LifeSciences has a 1 year low of $22.36 and a 1 year high of $50.78. The firm has a market capitalization of $1.96 billion, a P/E ratio of 30.01, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94.

Analysts Set New Price Targets

IART has been the subject of several research analyst reports. Truist Financial reduced their price target on shares of Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating for the company in a report on Tuesday. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Oppenheimer downgraded Integra LifeSciences from an “outperform” rating to a “market perform” rating in a report on Tuesday. Finally, JMP Securities cut their target price on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating on the stock in a research note on Tuesday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $36.80.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.